Cargando…

Electroacupuncture in treatment of Parkinson disease: A protocol for meta-analysis and systematic review

BACKGROUND: Parkinson disease (PD) is a worldwide spread neurodegenerative disorder. Dopamine replacement therapy is currently the mainstream treatment, which can alleviate the symptoms but induces motor complications. Electroacupuncture (EA) is beneficial for PD as an alternative medicine. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gai, Cong, Qiang, Tianyao, Zhang, Yuxin, Chai, Yuan, Feng, Wandi, Sun, Hongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837981/
https://www.ncbi.nlm.nih.gov/pubmed/33545923
http://dx.doi.org/10.1097/MD.0000000000023010
Descripción
Sumario:BACKGROUND: Parkinson disease (PD) is a worldwide spread neurodegenerative disorder. Dopamine replacement therapy is currently the mainstream treatment, which can alleviate the symptoms but induces motor complications. Electroacupuncture (EA) is beneficial for PD as an alternative medicine. However, few reliable clinical trials or objective systematic reviews are available to give a verdict on the effectiveness of EA in the treatment of PD. Thus, we evaluate the evidence for EA in PD patients by conducting this meta-analysis. METHODS: PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure, Chinese Scientific and Technology Journal database, WanFang Digital Periodicals, and Chinese Biomedical Literature Database (SinoMed) will be systematically searched for evidence by 2 authors individually. The analysis will be conducted by RevMan 5.3 software according to Cochrane Handbook. RESULTS: The efficacy and safety of EA for PD will be comprehensively assessed from the outcomes, including the effectiveness rate, scores of Unified Parkinson Disease Rating Scale, and Webster scale, superoxide dismutase, lipid peroxides, and dopamine content. CONCLUSION: This systematic review will provide evidence for whether EA can treatment PD. REGISTRATION INFORMATION: PROSPERO CRD42019120956.